According to research published in the Lancet, the vaccine trial was conducted on very few people, so the chances of safety and efficacy were low.
Russia announced last month that the vaccine had already been approved under the name “Sputnik V”.
The vaccine is named after the first satellite launched into space in 1957.
Western scientists are concerned about the lack of safety data. Some have warned that the immediate use of any vaccine could be dangerous.
Russia, on the other hand, has condemned the criticism of the investigation.
In the Lancet study, Russian researchers conducted two small trials in which 38 healthy adults aged 18 to 60 were vaccinated in two doses.
In the trial, each person was given a dose of the first dose of the vaccine and then a booster with the second dose 21 days later.
They were monitored in 42 days and all antibodies were produced within the first three weeks.
The report said that the data showed that the vaccine was “safe, tolerable” and had no adverse effects on healthy adult volunteers.
According to the report, the participants in the trials knew that they would be vaccinated.
The report said 76 participants in the trials would be monitored for 180 days.
According to Russia, a third phase of clinical trials will begin on “40,000 volunteers of different ages and at risk for corona.”
Noor Barzef of the Johns Hopkins Bloomberg School of Public Health said the research was “encouraging but small”. Keep in mind that they were not part of the regular trial.
He added that the vaccine did not yield any results in terms of efficacy in older groups, particularly those affected by Code 19.
He said in a commentary in the Lancet that demonstrating safety with the Covid 19 vaccine would be crucial not only to the acceptance of the vaccine but also to the widespread confidence in vaccination.
On the other hand, this week the United States urged the states to be ready for the immunization of Code 19 two days before the November presidential election.
Concerns have been raised that President Donald Trump’s administration is stepping up research according to a political timetable.
Russia says industrial production of its version (vaccine) is expected from September